LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
The Neuroscience of Parkinson’s Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condit… Read more
LIMITED OFFER
Immediately download your ebook while waiting for your print delivery. No promo code needed.
DIAGNOSIS AND MANAGEMENT IN PARKINSON'S DISEASE
Foreword
Virginia Bottomley
Preface
I. Introductory Chapters and Setting the Scene
1. Progression of symptoms in Parkinson's disease
Lucilla Parnetti
2. Cellular pathophysiology and basal ganglia dysfunction in Parkinson's disease: An Overview
Heinz Reichmann and Kai Felix Loewenbrueck
3. The role of environmental toxins and inflammation in Parkinson’s disease pathophysiology: a historical perspective and research-based evidence
Heinz Reichmann and Kai Felix Loewenbrueck
4. Risk factors in Parkinson's Disease: genetic and nongenetic
Evangelos Evangelou
5. Recent developments in the etiology, treatment and potential therapeutic targets for Parkinson's Disease: a focus on biochemistry
Athanasios Alexiou
6. Facial emotions and Parkinson's disease
G. Di Gennaro and Marco De Risi
7. The role of the circadian system in Parkinson’s Disease
G. Willis
8. Parkinson's disease and social media
Ibrahim S. Al-Busaidi
9. Sleep in Parkinson's disease
Marcelo M. S. Lima
10. Recurrent falls in Parkinson's disease
Lorena Rosa Santos de Almeida
11. Parkinsons patients deciding their own treatment
J. Koerts
12. Visual impairment in Parkinson's disease
Alessandro Arrigo
13. Autonomic problems in Parkinson’s disease: a focus on the bladder
Ryuji Sakakibara
14. Autonomic problems in Parkinson’s disease: a focus on the bowel
Ryuji Sakakibara
15. Linking and comparing nonmotor symptoms in ageing and Parkinson’s disease
Petra Bago Rozankovic
16. Progression of motor symptoms in Parkinson's Disease
Joana Ribeiro and Daniela Vieira
17. The stigma of Parkinson's disease
Benjamin K.P. Woo
II. Biomarkers, Instruments, Diagnosis and Assessments
18. Better neuroradiological approaches for the diagnosis of early stage Parkinson's disease patients
Tatsuro Mutoh
19. Use of positron emission tomography (PET) as a diagnostic and differential diagnostic tool in Parkinsonian syndromes
Maja Trost
20. Finger typing for the detection of early Parkinson's Disease
Warwick Adams
21. CSF biomarkers of Parkinson's disease
P. Lewitt
22. Application of eye movement tasks as an aid to understanding Parkinson's disease pathophysiology
Kikuro Fukushima
23. Measuring quality of life
Pablo Martinez Martin and Camen Rodriquez-Blazquez
24. Clinically assessing cognitive function in Parkinson’s disease
Ryan Anderton
III. Pharmacological Treatments, Other Agents and Strategies
25. Good news for the drug therapy of Parkinson`s disease
L. Bergantin
26. Dopamine Agonists and Parkinson’s disease: an overview
Aloke K. Dutta
27. Management with apomorphine in Parkinson’s disease
Manon Auffret
28. Management with MAO-B Inhibitors in Parkinson’s disease
T. Mueller
29. Management with antibiotics in Parkinson’s disease
Elaine Del-Bel and Mariza Bortolanza
30. Administration of dopamine in the brain in Parkinson’s disease
David Devos
31. Placebo and nocebo effects in Parkinson's disease
Fabrizio Benedetti
32. Levodopa-induced dyskinesias
N. S. Narayanan and Stephanie Alberico
33. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease
Miguel Abellanas and M. Aymerich
IV. Non-Pharmacological, Novel and Other Treatment Procedures
34. Deep Brain Stimulation Surgery in Parkinson's Disease
Hesham Abboud
35. Gene delivery for Parkinson’s disease
M. Airavaara and Andrii Domanskyi
36. Transdifferentiation of glial cells into dopamine neutrons via viral vectors/ Introducing transgenes into cells into the brain
M. Airavaara and Andrii Domanskyi
37. Urso- and tauroursodeoxycholic acids as anti-apoptotic agents: Modulation of Parkinson's disease
Noha Abdelkader
38. Interlinking potential therapy with botulinum neurotoxin A and Parkinson's disease
Andreas Wree
39. Neuropeptide CART (cocaine-amphetamine-regulated transcript) and usage in Parkinson's disease
P. Mao
40. Photobiomodulation as a neuroprotective strategy for Parkinson’s disease
Daniel M. Johnstone
41. Assisted devices in Parkinson's disease
Roongroj Bhidayasiri
GENETICS, NEUROLOGY, BEHAVIOR, AND DIET IN PARKINSON'S DISEASE
Foreword
Virginia Bottomley
Preface
I. Genetics, Molecular and Cellular Biology
1. LRRK2 genes in Parkinson’s disease: from genetics to pathobiology
Elisa Greggio and Susanna Cogo
2. Alpha-synuclein gene and Parkinson’s disease
Leonidas Stefanis
3. The DJ-1 gene and protein: links with Parkinson's Disease
Paul R. Fisher
4. Gene expression in the connection between 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and tyrosine hydroxylase
Gelareh Alam and Jason Richardson
5. Linking GBA variants and Parkinson's disease
Mathias Toft
6. Astrocytes and microglia in Parkinson’s disease and its animal models
Katarzyna Z. Kuter
7. Autophagy in Parkinson’s disease
Sandra Morais Cardoso and Nilza Manadas
8. Mitochondria in Parkinson’s disease
Sabrina Buettner
9. Signal transduction in Parkinson's disease
Mattia Volta
10. Oxidative stress signaling and regulated cell death in Parkinson’s disease
Marlene Jimenez-Del-Rio and Carlos Velez-Pardo
11. Subcellular-specific alpha-synuclein in Parkinson's Disease
Simon Geir Moller and Benjamin Rosen
12. MC1R in Parkinson's disease and association with melanoma risk
Susana Puig and Gemma Tell-Marti
13. Energy regulation and Parkison's disease
Kah-Leong Lim
14. Linking rotigotine, Parkinsons disease and brain BDNF
H. Kunugi
II. Neurology, Physiology and Imaging
15. The different syndromes in Parkinson’s disease: an overview
Maria Stamelou and Nikolaos Giagkou
16. Neuromolecular imaging in Parkinson’s disease
P. Broderick
17. Interlinking brain mapping and Parkinson's disease: MRI analysis, nigrosome 1 and nigrosome 4
Eung Yeop Kim
18. Interconnecting Parkinson’s disease, computed tomography (CT) and microelectrode recording in deep brain stimulation
Sepehr Sani and Ryan B. Kochanski
19. Linking diffusion tensor imaging (DTI), microstructures and Parkinson’s disease
Yu Zhang
20. Hypointensity in the substantia nigra pars compacta in Parkinson’s disease
Xiaoping Hu and Jason Langley
21. Vagal motoneurons in Parkinson’s disease
Joshua A. Goldberg and Ruth Musgrove
22. Circadian clock disruption and neuroinflammation in Parkinson’s disease: a new perspective
Elisabetta Lauretti and Domenico Pratico
23. Motor cortex stimulation in Parkinson’s disease
A. Lavano
24. Action programming disorders associated with Parkinson's Disease
Kenneth M. Heilman
25. The striatal medium spiny neurons (MSNs): what they are and how they link with Parkinson's disease
Fu-Ming Zhou
26. Disruptions of frontostriatal language functions in Parkinson's Disease
Adolfo M. Garcia
27. Synuclein and neuroinflammation in Parkinson's disease
Luigi Bubacco
28. Tau and its interactions with other proteins in neurodegenerative disease
Paul R. Fisher
29. Dopamine and the renin-angiotensin system in neuronal tissues Parkinson's Disease
Jose Luis Labandeira Garcia
30. Restoring dopamine levels in Parkinson’s disease
Henning Ulrich and Ágatha Oliveira-Giacomelli
III. Behaviour and Psychopathology
31. Motivation and motivational aspects of Parkinson's disease
Abdeslam Chagraoui
32. Linking anxiety, cognitive and sensory deficits to gait and balance in Parkinson’s disease
Quincy J. Almeida
33. Interlinking motor program of gait and bradykinesia in Parkinson's disease
Tateo Warabi
34. Olfactory features in Parkinson's disease
Marcelo M. S. Lima
IV. Diet And Nutrition
35. Interlinking dementia in Parkinson's disease: and nutritional correlates of body composition
Arthur Oscar Schelp
36. The role of the gut microbiota in Parkinson's disease
Ryan Anderton and Jade Kenna
37. Swallowing defects in Parkinson’s disease
Maira Rozenfeld Olchik
38. The Mini Nutritional Assessment (MNA ) and applications to Parkinson’s disease
Svetlana Tomic
39. Bacopa monnieri extract and Parkinson’s disease
Ravikumar Hosamani
V. Models, Modelling and Resources
40. 6-hydroxydopamine-induced model of Parkinson’s disease
Katarzyna Kaczynska
41. Knockdown transgenic Drosophila and Parkinson’s disease
Carlos Velez-Pardo and Marlene Jimenez-Del-Rio
42. Evidence for neuroprotection in animal models of Parkinson’s disease
John Mitrofanis
43. Modelling with the A53T alpha-synuclein model of Parkinson’s disease
CW Ip
44. Linking the leucine-rich repeat kinase 2 (LRRK2) gene, animals models and Parkinson’s disease
Yulan Xiong
Resources
Rajkumar Rajendram
CR
VP